clopidogrel


Also found in: Thesaurus, Medical, Wikipedia.
Related to clopidogrel: clopidogrel bisulfate

clo·pid·o·grel

 (klō-pĭd′ə-grĕl′)
n.
A drug, C16H16ClNO2S, given in the form of its bisulfate, that inhibits platelet aggregation and is used in the treatment of patients with peripheral arterial disease, certain forms of angina, or a recent history of heart attack or stroke.

[c(h)lo(ro)- + p(yr)id(ine) + -grel, platelet aggregation inhibitor suffix (ultimately from aggregation).]
Translations

clopidogrel

n clopidogrel m
References in periodicals archive ?
Zainab Ali, a College of Pharmacy (CPH) MSc student from Qatar University (QU) studying clinical pharmacy, conducted a novel observational study of clopidogrel genetics in Qatar in her master's thesis which was defended recently under the supervision of CPH associate professor and the head of clinical training Dr Hazem Elewa.
Results: A total of 60 patients met the inclusion criteria of the study; 36 (60%) were taking a combination of clopidogrel 75mg plus Aspirin 75 mg and 12 (20%) received Aspirin 75 mg daily while 12 (20%) were getting other regimens.
Many combinations of antiplatelet therapy are possible but, in the United States, DAPT denotes ASA 81 mg/d plus any of the 3 P2Y12 inhibitors: clopidogrel, prasugrel, and ticagrelor.
To the Editor: Current treatment guidelines for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) recommend dual antiplatelet therapy, a combination of aspirin and a P2Y12 inhibitor (i.e., clopidogrel, prasugrel, and ticagrelor) for a minimum of 12 months.
The drug regimen, known as dual-antiplatelet therapy, or DAPT, includes low-dose aspirin plus Clopidogrel (Plavix[TM]), ticagrelor (Brilinta[TM]) or prasugrel (Effient[TM]).
THURSDAY, May 17, 2018 (HealthDay News) -- The combination of clopidogrel and aspirin is associated with reduced risk of major ischemic events but increased risk of major hemorrhage among patients with minor ischemic stroke or high-risk transient ischemic attack (TIA), according to a study published online May 16 in the New England Journal of Medicine.
IN THE LATE 2000s, several large epidemiologic studies suggested that proton pump inhibitors (PPIs) increase the risk for MI in users of clopidogrel. There was a proposed mechanism: PPIs competitively inhibit cytochrome P450 isoenzymes, which blocked clopidogrel activation and, ex vivo, increased platelet aggregation.
DAPT with clopidogrel reduced the 1-year incidence of cardiovascular events by approximately 20% compared with aspirin monotherapy.
Antiplatelet medications that work by inhibiting the platelet P2Y12 receptor are increasingly used therapeutically: clopidogrel, prasugrel, ticagrelor, and cangrelor.
Clopidogrel besylate is an anti-platelet drug that inhibits the ability of platelets to clump together as part of a blood clot [11].